A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes

Benzer Materyaller

• Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
  Yazar:: Kapitza, Christoph, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial
  Yazar:: Thrasher, James, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
  Yazar:: Shah, Viral N., ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
  Yazar:: Heise, Tim, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)
• Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
  Yazar:: Garg, Satish K., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)